key papers
key papers
The papers that changed practice or thinking, each explained: what it found, what it means, and what to be careful about.
1 key papers
| Diagnoses | Products | |||||
|---|---|---|---|---|---|---|
Lecanemab in Early Alzheimer’s Disease (CLARITY AD) van Dyck CH, et al. · New England Journal of Medicine 2023 The published CLARITY AD paper reports the phase 3 lecanemab trial in early Alzheimer’s disease. Read the paper and the FDA communication together. | New England Journal of Medicine | Alzheimer’s disease | Lecanemab |